HAE vs. XRAY, MMSI, QDEL, NEOG, ICUI, STAA, ATRI, ANIK, OSUR, and CERS
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), QuidelOrtho (QDEL), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Atrion (ATRI), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), and Cerus (CERS). These companies are all part of the "health care supplies" industry.
Haemonetics (NYSE:HAE) and DENTSPLY SIRONA (NASDAQ:XRAY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
DENTSPLY SIRONA received 73 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 61.21% of users gave DENTSPLY SIRONA an outperform vote while only 60.89% of users gave Haemonetics an outperform vote.
Haemonetics has a net margin of 8.98% compared to DENTSPLY SIRONA's net margin of -2.41%. Haemonetics' return on equity of 22.25% beat DENTSPLY SIRONA's return on equity.
Haemonetics has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
Haemonetics currently has a consensus target price of $108.67, indicating a potential upside of 29.24%. DENTSPLY SIRONA has a consensus target price of $35.22, indicating a potential upside of 25.75%. Given Haemonetics' higher probable upside, equities research analysts plainly believe Haemonetics is more favorable than DENTSPLY SIRONA.
In the previous week, Haemonetics had 3 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 14 mentions for Haemonetics and 11 mentions for DENTSPLY SIRONA. Haemonetics' average media sentiment score of 0.67 beat DENTSPLY SIRONA's score of 0.48 indicating that Haemonetics is being referred to more favorably in the media.
99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Haemonetics has higher earnings, but lower revenue than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Summary
Haemonetics beats DENTSPLY SIRONA on 12 of the 18 factors compared between the two stocks.
Get Haemonetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Haemonetics Competitors List
Related Companies and Tools
